Address
Sussex Innovation Centre
Science Park Square
Falmer Brighton
United Kingdom
Contact
Daniel Hynes+44 7903099712
dh@destinypharma.com
Website
XF Drug Platform
Small molecule drug platform rapidly bactericidal with unique mechanisms of action
A platform of porphyrin molecules with antimicrobial activity intended for topical application for the treatment or prevention of infection
The XF drug platform has a novel, ultra-rapid mechanism that reduces the chance of bacteria becoming resistant to its action.
Technology:
Microorganisms:
Application:
Development stage:
- Infection prevention
- Antimicrobial compounds
- Antimicrobial stewardship
- Microbial diagnostics
- Antimicrobial compound/strategy
- Removal antibiotics/bacteria
Microorganisms:
- Bacteria
- Viruses
- Fungi
- Yeasts
- Parasites
Application:
- Human
- Veterinary
- AgriFood
- Environmental
- Other
Development stage:
- Development
- Research
- Validation
- Market entry
- Marketed product
Organization:
Partnering:
Funding organisation:
Infectious disease area:
Geographic origin:
- Company
- Academia
- Institute
- NGO
- Government
Partnering:
- Yes
- License
- Co-develop
- Outsource
- Joint Venture
- Sell
Funding organisation:
Infectious disease area:
Geographic origin:
Co-development, licensing, and outsourcing are all parts of the Destiny pharma business model.
Destiny Pharma plc is a clinical stage, virtual biotech company
N.A.
